The R&D team at AURA Biotech has achieved a breakthrough in the field of rapid diagnostic testing. The team has officially completed the phased clinical and preclinical data for its next-generation IVD all-in-one rapid test kit, with the Taiwan regulatory registration number expected soon. In response to the unpredictable global public health landscape of the post-pandemic era, AURA Biotech remains committed to precision, speed, and stability as the primary objectives of its R&D solutions, all supported by the Group's profound technical expertise.
The core of this R&D achievement lies in the significant enhancement of detection sensitivity and specificity. More importantly, by leveraging the same carbon nanotube (CNT) technology platform used in our COVID-19 rapid tests, we have successfully applied this methodology to the field of influenza-like illnesses. Our new 3-in-1 rapid test kit—which combines Influenza A, Influenza B, and RSV—drastically improves the diagnostic efficiency and sensitivity of respiratory virus screening.
Currently, AURA Biotech is actively developing a wide range of relevant IVD diagnostic reagents, including HMPV, H. pylori, oral cancer, and emerging drug screening. We have initiated strategic dialogues with medical sectors, public health authorities, government agencies, and global medical trade partners. Our plan is to introduce more IVD diagnostic reagents and technologies to the medical frontline to alleviate the strain on manpower and the increasing imbalance in the nurse-to-patient ratio. Through these commitments, the Group aims to solidify its leading position in the IVD diagnostic reagent market both in Taiwan and globally.
We firmly believe that only innovation built upon solid clinical evidence can provide the most stable protection for the public; this is the steadfast commitment of the AURA Group throughout our cross-disciplinary transformation.
